Veracyte, Inc. Announces That New Study Suggests the Number of Patients at Risk for Unnecessary Thyroid Surgery is Likely on the Rise
4/19/2013 8:37:04 AM
More...
|
Veracyte, Inc. Announces That New Study Suggests the Number of Patients at Risk for Unnecessary Thyroid Surgery is Likely on the Rise
4/17/2013 9:34:40 AM
More...
|
Veracyte, Inc. Announces Appointment of Shelly D. Guyer as Chief Financial Officer
4/12/2013 6:32:41 AM
More...
|
Veracyte, Inc. Announces Results of Study Assessing Use of BRAF Mutation Testing With Its Afirma® Gene Expression Classifier
3/12/2013 10:32:00 AM
More...
|
Veracyte, Inc. Announces UnitedHealthcare Coverage Policy for the Afirma® Gene Expression Classifier
3/8/2013 9:51:14 AM
More...
|
New Article in PLOS Currents: Evidence on Genomic Tests Supports Use of Veracyte, Inc.'s Afirma® Gene Expression Classifier to Resolve Ambiguous Thyroid Nodule Biopsies
2/15/2013 9:48:46 AM
More...
|
Veracyte, Inc. Announces That New Guidelines Include Molecular Testing for Indeterminate Thyroid Nodules to Reduce Unnecessary Surgeries
1/7/2013 10:40:41 AM
More...
|
Veracyte, Inc. Announces Publication of Analytic Validity Study for Its Afirma® Gene Expression Classifier
10/22/2012 10:11:36 AM
More...
|
Veracyte, Inc. Receives New York State License for Afirma® Gene Expression Classifier
8/29/2012 9:40:16 AM
More...
|
New Study Suggests That Use of Veracyte, Inc.'s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results
7/17/2012 10:25:46 AM
More...
|
|